SCHEDULE 13G/A 0001415889-25-010640 0001757283 XXXXXXXX LIVE 2 Ordinary Shares, nominal value Euro 0.01 per share 12/31/2025 0001756594 Inventiva S.A. 46124U107 50 rue de Dijon Daix I0 21121 Rule 13d-1(c) Andera Partners I0 0.00 14114476.00 0.00 14114476.00 14114476.00 7.7 OO BioDiscovery 6 FPCI I0 0.00 14114476.00 0.00 14114476.00 14114476.00 7.7 OO Stephane Bergez I0 0.00 14114476.00 0.00 14114476.00 14114476.00 7.7 IN Francois Xavier Mauron I0 0.00 14114476.00 0.00 12296295.00 14114476.00 7.7 IN Inventiva S.A. 50 rue de Dijon, Daix, I0, 21121 . The names of the persons filing this report (collectively, the "Reporting Persons") are: BioDiscovery 6 FPCI ("BioDiscovery 6") Andera Partners ("Andera") Stephane Bergez ("Bergez") Francois Xavier Mauron ("Mauron") The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13G/A. 2 place de Rio de Janeiro 75008 Paris France BioDiscovery 6 France Andera France Bergez France Mauron France Y Row 9 of each Reporting Person's cover page to this Schedule 13G/A sets forth the aggregate number of securities of the Issuer beneficially owned by such Reporting Person as of December 31, 2025 and is incorporated by reference. BioDiscovery 6 is the record holder of (i) 12,296,295 ordinary shares and (ii) 1,818,181 American Depositary Shares ("ADS") of the Issuer, representing an aggregate of 1,818,181 ordinary shares. Voting and dispositive decisions with respect to the securities held by BioDiscovery 6 are made by its management company, Andera. The managing partners of Andera are Bergez and Mauron. As a result, each of the Reporting Persons may be deemed to beneficially own the securities held by BioDiscovery 6. CUSIP Number 46124U107 has been assigned to the ADS of the Issuer, which are quoted on the Nasdaq Global Market under the symbol "IVA". Each ADS represents one ordinary share of the Issuer. No CUSIP has been assigned to the Issuer's ordinary shares. Row 11 of each Reporting Person's cover page to this Schedule 13G/A sets forth the percentages of the securities of the Issuer beneficially owned by such Reporting Person as of December 31, 2025 and is incorporated by reference. The percentage set forth in each row 11 is based upon 183,956,467 ordinary shares outstanding as of November 17, 2025, as reported in the Issuer's Registration Statement on Form F-3 filed with the Securities and Exchange Commission (the "SEC") on November 13, 2025. Row 5 of each Reporting Person's cover page to this Schedule 13G/A sets forth the sole power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person as of December 31, 2025 and is incorporated by reference. Row 6 of each Reporting Person's cover page to this Schedule 13G/A sets forth the shared power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person as of December 31, 2025 and is incorporated by reference. Row 7 of each Reporting Person's cover page to this Schedule 13G/A sets forth the sole power to dispose or to direct the disposition of securities of the Issuer beneficially owned by such Reporting Person as of December 31, 2025 and is incorporated by reference. Row 8 of each Reporting Person's cover page to this Schedule 13G/A sets forth the shared power to dispose or to direct the disposition of securities of the Issuer beneficially owned by such Reporting Person as of December 31, 2025 and is incorporated by reference. Y Y Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. Exhibit 99.1 Joint Filing Agreement (incorporated by reference to Exhibit 99.1 to the Schedule 13G filed by the Reporting Persons with the SEC on April 14, 2025). Andera Partners /s/ Stephane Bergez 02/17/2026 BioDiscovery 6 FPCI /s/ Stephane Bergez 02/17/2026 Stephane Bergez /s/ Stephane Bergez 02/17/2026 Francois Xavier Mauron /s/ Francois Xavier Mauron 02/17/2026